ALS-L1023

ALS-L1023 is an oral angiogenesis inhibitor derived from the ethyl acetate extract of *Melissa officinalis* L. (lemon balm) leaves. It is being developed primarily for the treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and wet age-related macular degeneration (AMD). The drug acts by inhibiting angiogenic factors such as vascular endothelial growth factor A (VEGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), and matrix metalloproteinases (MMPs). Preclinical and clinical studies suggest that ALS-L1023 reduces hepatic fat content, alleviates liver fibrosis, and may improve visual outcomes in AMD by protecting retinal pigment epithelial cells from oxidative stress-induced apoptosis. The drug has shown a favorable safety profile in clinical trials[1][2][5][6].

Brand names

AL101-MASHAL-101-MASHAL 101-MASH

Other names

Melissa leaf ethyl acetate dried extractlemon balm extract (ALS-L1023)